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ABSTRACT
Dysregulation of Na+/H+ exchanger isoform one (NHE1) activity is a hallmark 
of cells undergoing tumorigenesis and metastasis, the leading cause of patient 
mortality. The acidic tumor microenvironment is thought to facilitate the development 
of resistance to chemotherapy drugs and to promote extracellular matrix remodeling 
leading to metastasis. Here, we investigated NHE1 as a co-adjuvant target in paclitaxel 
chemotherapy of metastatic breast cancer. We generated a stable NHE1-knockout 
of the highly invasive, triple-negative, MDA-MB-231 breast cancer cells. The NHE1-
knockout cells proliferated comparably to parental cells, but had markedly lower rates 
of migration and invasion in vitro. In vivo xenograft tumor growth in athymic nude 
mice was also dramatically decreased compared to parental MDA-MB-231 cells. Loss 
of NHE1 expression also increased the susceptibility of knockout cells to paclitaxel-
mediated cell death. NHE1 inhibition, in combination with paclitaxel, resulted in a 
dramatic decrease in viability, and migratory and invasive potential of triple-negative 
breast cancer cells, but not in hormone receptor-positive, luminal MCF7 cells. Our 
data suggest that NHE1 is critical in triple-negative breast cancer metastasis, and its 
chemical inhibition boosts the efficacy of paclitaxel in vitro, highlighting NHE1 as a 
novel, potential co-adjuvant target in breast cancer chemotherapy.
INTRODUCTION
In normal and neoplastic cells, the maintenance 
of pH homeostasis is chiefly regulated by the Na+/H+ 
exchanger isoform one (NHE1). NHE1 is a ubiquitously 
expressed, integral plasma membrane protein comprised of 
a membrane-traversing domain that facilitates ion flux, and 
a cytoplasmic C-terminal domain that regulates exchanger 
activity. Ion flux occurs with the electroneutral exchange 
of one intracellular proton for one extracellular sodium 
ion, and is driven by the transmembrane Na+ gradient. In 
conditions of low intracellular pH (pHi), excess protons 
allosterically activate NHE1, facilitating proton extrusion 
and a return to homeostatic pHi. NHE1 activity therefore 
maintains pHi and has been shown to play an important 
role in the regulation of cell volume and shape, while also 
promoting cell growth, proliferation, differentiation, and 
apoptosis [1]. NHE1 is present on the nuclear membranes 
of various cell types including aortic and liver tissues, and 
cardiomyocytes, suggesting that it is also involved in the 
modulation of intranuclear pH [2]. Regulation of NHE1 
activity is thus critical and tightly controlled by multiple 
signaling pathways (e.g. MAPK, ERK1/2), and initiated 
by growth factors or hormonal stimulation that either 
directly or indirectly affect the phosphorylation state of 
its C-terminal domain. In addition, several intracellular 
proteins and lipids (e.g. PIP
2
, CHP1/2/3, actin binding 
proteins ezrin-radixin-moesin, calmodulin, carbonic 
anhydrase II) regulate Na+/H+ exchange via interaction 
with the C-terminal tail of NHE1 [3]. Whether all these 
protein and lipid associations are retained in breast cancer 
cells is not clear [4]. 
In neoplastic cells, NHE1 activity is of special 
importance. The dysregulation of NHE1 activity is now 
considered a hallmark of cells undergoing tumorigenesis. 
NHE1 becomes constitutively active in the transformed 
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phenotype, resulting in a reversal of the normal pH 
gradient in many cancer cells. This raises pHi with a 
concomitant decrease in extracellular pH. The low 
extracellular pH (pHe) and decreased vascularization 
associated with rapid tumor growth also stimulate directed 
cell migration and invasion, resulting in the metastatic 
dissemination of tumor cells to sites distant from the 
primary tumor [5]. Importantly, the acidic extracellular 
microenvironment stimulates extracellular protease 
activity, extracellular matrix remodeling and cell invasion 
[6]. It may also contribute to the development of multidrug 
resistance of tumor cells to many chemotherapy drugs, 
which also hinders immune rejection of these tumors [7]. 
Weakly basic chemotherapy agents (e.g. doxorubicin) 
are likely protonated in acidic pHe, which impedes their 
entrance into cells and prevents them from reaching their 
intracellular molecular targets [8, 9]. In mice, xenograft 
tumors of lowly invasive MCF7 breast cancer cells were 
much more sensitive to doxorubicin at an extracellular 
pH of 7.4 than 6.8 in vivo [10]. Paclitaxel, which has a 
complex structure that includes both an acidic and basic 
domain, is also less cytotoxic at low pHe [11]. To date, 
there is no evidence to suggest that pharmacological 
inhibitors of NHE1 could be effective chemotherapy 
agents in humans [12]. However, it stands to reason that 
manipulating the tumor microenvironment through the 
modulation of NHE1 activity could aid in chemotherapy 
treatment strategies in a co-adjuvant manner post-surgical 
intervention or, alternatively, in a co-neoadjuvant manner 
prior to surgery.
The initial development of NHE1-specific inhibitors 
was driven by the need to counter the adverse effects 
of excessive exchanger activity in the mammalian 
myocardium. Amiloride, a potassium-sparing diuretic 
that has been used clinically, is a NHE inhibitor [13, 
14]. Several other drugs have since been developed and 
investigated in terms of their increased selectivity and 
potency towards NHE1 inhibition [15]. Testing these 
NHE1 inhibitors for their anti-cancer properties is ongoing 
[16]. The two major families of these compounds are: 
the pyrazine derivatives (e.g. 5-(N,N-hexamethylene)
amiloride), 5-(N,N-dimethyl)amiloride, 5-(N-ethyl-N-
isopropyl-amiloride)), and the benzoylguanidines (e.g. 
cariporide, eniporide, HOE-694) [13]. The successful use 
of amiloride as an anti-cancer therapy in animal models 
was recently reviewed [14]. 
Here, we propose that, since pH regulation is 
pivotal in the switch from the normal to the neoplastic to 
the metastatic phenotype of cancer cells, that inhibition 
of NHE1 can be used as a target to increase the efficacy 
of anti-cancer drugs. Recent studies have lent credence to 
this hypothesis. One study examined MCF7 breast cancer 
cells, representative of the estrogen receptor-positive 
luminal subtype of breast cancer. NHE1 knockdown 
or inhibition with 5-(N-ethyl-N-isopropyl) amiloride 
sensitized these cells to apoptosis induced by cisplatin 
[17]. 
Triple-negative breast cancer is a heterogeneous 
disease that accounts for 10-20% of all metastatic 
breast cancers. Triple-negative breast cancer lacks the 
expression of estrogen and progesterone receptors, and 
human epithelial growth factor 2 receptors (HER2; also 
known as ErbB2), and shares characteristics with basal-
like, claudin-low, and BRCA1-related breast cancer. 
It is most commonly diagnosed in younger women (< 
50 years) and ultimately results in poor prognosis [18]. 
To date, no targeted therapies exist for the treatment of 
metastatic triple-negative breast cancer other than surgery 
and cytotoxic chemotherapy, primarily with taxanes (e.g. 
paclitaxel) or anthracyclines (e.g. doxorubicin) [19]. In 
this study, we investigated NHE1 as a target for adjuvant 
therapy in highly invasive, triple-negative breast cancer 
cells. We used specific NHE1 inhibitors, HMA [5-(N,N-
hexamethylene) amiloride)], representative of the 
pyrazine class of amiloride derivatives, and EMD87580 
[2-methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine)], 
representative of the benzoylguanidines, to increase 
the susceptibility of triple-negative breast cancer cells 
to paclitaxel. Paclitaxel belongs to the taxane group of 
pharmaceuticals that was introduced into the clinical 
treatment of breast and ovarian cancer in the 1990s [20]. 
It is still considered the most effective treatment option 
for breast cancer patients and is US-FDA approved as 
a second line chemotherapy for those with advanced 
metastatic disease [21]. We report that low-dose paclitaxel-
mediated cell death is increased by the simultaneous 
administration of either EMD87580 or HMA in triple-
negative breast cancer cells. Furthermore, we validate the 
importance of NHE1 function by generating an NHE1-
knockout cell line (231-KO) for comparison with the 
parental MDA-MB-231 cells that endogenously express 
NHE1. The 231-KO cells showed markedly less xenograft 
tumor growth than the parental MDA-MB-231 cells over 
time. Taken together, our data show, for the first time, that 
the chemical inhibition or loss of NHE1 expression in 
invasive, metastatic triple-negative breast cancer cell lines 
enhances their susceptibility to paclitaxel-mediated cell 
death. This study enforces the idea that NHE1 may be key 
in the development of novel, tumor microenvironment-
targeted chemotherapeutic strategies for the treatment of 
triple-negative breast cancers.
RESULTS:
Na+/H+ exchange activity, but not NHE1 
expression, is elevated in MDA-MB-231 (231-WT) 
cells in tumor mimetic conditions
To examine the role of NHE1 in tumor cells we 
made a knockout of the protein in the parental MDA-
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MB-231 cells (231-WT). Western blot analysis was 
used to examine endogenous expression of NHE1 in 
the NHE1-knockout (231-KO), compared to the 231-
WT cells, MCF7 and MDA-MB-468 cells. NHE1 was 
consistently observed as a band at approximately 100 
kDa in multiple lysate preparations (Fig. 1A). A second 
smaller band was also observed and is typical of a 
partially or de-glycosylated NHE1 protein. As expected, 
the stable NHE1-knockout (231-KO) cells showed no 
NHE1 protein expression. We also compared the level 
of NHE1 protein in either stimulated (low-serum (0.2%) 
media) or unstimulated (10%-serum supplemented media) 
conditions as previously described [22]. When the level of 
NHE1 was quantitatively compared to that of actin, there 
was no up-regulation of NHE1 expression in any cell type 
under stimulated conditions (N=5, see Fig. 1 for example). 
We examined the NHE1 activity of the tumor cell 
lines in stimulated or unstimulated conditions (Fig. 1B, C). 
As expected, stable NHE1-knockout MDA-MB-231 (231-
KO) cells showed no demonstrable Na+/H+ exchanger 
activity either in stimulated or unstimulated conditions. 
When we examined the relative Na+/H+ exchange activity 
of MDA-MB-231 and MCF7 (P<0.001, N=8), and MDA-
MB-468 (P<0.01, N=8) breast cancer cells, we found that 
it was significantly higher in cells that were serum-starved 
for 24 hr. prior to measurement of pHi (Fig. 1B, C). 
To further characterize differences between parental 
and NHE1-knockout MDA-MB-231 cells, we studied cell 
proliferation in unstimulated and stimulated conditions 
over 48 hr. In serum-deprived conditions typical of the 
tumor microenvironment, both 231-WT and 231-KO 
cells were more proliferative compared to MCF7 and 
MDA-MB-468 cells over 48 hr. (Fig. 2A; P<0.001, 
N=5). There was no difference in proliferation rates 
between stimulated 231-WT and 231-KO cells. All cell 
types had similar rates of proliferation in unstimulated 
conditions (data not shown). We also examined the effect 
of increasing concentrations of paclitaxel on cell viability. 
Interestingly, stimulated 231-KO cells appeared to be 
more susceptible to paclitaxel-mediated cytotoxicity at 
0.1 nM and higher concentrations (P<0.05 to P<0.001, 
N=3) compared to 231-WT cells (Fig. 2B). In addition, 
there were no significant changes in the viability of MCF7 
and MDA-MB-468 cells in response to paclitaxel at the 
tested concentrations. In other experiments, we examined 
the effect of NHE1 inhibitors on cell viability. EMD87580 
was not cytotoxic to cells at up to 100 μM, but high 
concentrations of HMA (100 μM) resulted in less than 
Figure 1: Na+/H+ exchanger expression and activity 
in parental MDA-MB-231 (231-WT) and NHE1-
knockout cells (231-KO). A, Western blot analysis of NHE1 
expression in 231-WT, 231-KO, MDA-MB-468 and MCF7 cells 
probed with anti-NHE1 antibody. B, Changes in intracellular 
pH (pHi) in response to acid loading. Examples of traces 
illustrating the recovery from an acute acid load. Intracellular 
pH was examined in cells that were transiently acidified using 
ammonium chloride. Periods of NH4Cl, NaCl and Na-free 
solution are indicated. An entire example of the recovery is 
indicated for stimulated 231-WT cells (231s). An example of 
recovery is indicated for unstimulated 231-WT cells (231u) and 
MDA-MB-231 NHE1-knockout cells (231-KO). Fluorescence 
of BCECF, a pH-sensitive indicator dye, was used to record 
and quantify changes in pHi post-acute acid load induced by 
ammonium chloride. NHE1 activity was calculated from the 
slope of the first 20 sec of recovery from acidification and was 
expressed as ∆pH/sec. C, Relative rate of Na+/H+ exchange 
activity of 231-KO cells relative to 231-WT cells, and in MDA-
MB-468 and MCF7 cells. Values of ΔpH/sec from 231-WT and 
231-KO cells were normalized to the unstimulated control values 
for 231-WT cells. Data for MCF7 and MDA-MB-468 were 
normalized to their control unstimulated values respectively. No 
discernible exchanger activity was detected in the knockout cells. 
Background drift and buffering capacity were not significantly 
different between cell types. In stimulated conditions (0.2% 
serum), NHE1 activity is significantly increased in 231-WT, 
MDA-MB-468 and MCF7 cells [*P<0.001, +P<0.01, N=8]. 
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10% viability in all cell types (data not shown). 
Knockout of NHE1 inhibits the growth of MDA-
MB-231-driven subcutaneous tumors in vivo in 
athymic nude mice 
To assess the tumor-promoting potential of MDA-
MB-231 cells in relation to NHE1 expression, tumor 
growth of both 231-WT and 231-KO cells was examined 
as xenografts in athymic nude mice over 60 days. As 
shown in Fig. 3A, tumors derived from parental MDA-
MB-231 cells (N=8) increased in volume over time, while 
the growth of 231-KO tumors was minimal, or not at all, 
with small tumors formed in only 3 of 8 injection sites. At 
28 days, the observed differences in tumor growth were 
significant (P<0.05). At 35 days and onwards, growth of 
231-WT tumors was markedly increased (P<0.001), but no 
difference was observed in 231-KO tumor growth. While 
heterogeneity of excised tumors was observed within 
the 231-WT group, the importance of NHE1 in tumor-
promotion was evident from the lack of tumor formation 
with the 231-KO cells (Fig. 3B). 
NHE1 inhibition potentiates the effect of 
paclitaxel on cell viability 
As noted above, we found that stimulated 231-WT 
cells have elevated Na+/H+ exchanger activity independent 
of changes in protein expression. We hypothesized that 
with NHE1 inhibition they would be more susceptible to 
paclitaxel-induced cell death because of a dependence on 
this elevated rate of Na+/H+ exchange. We indeed found 
this to be the case. The viability of stimulated 231-WT 
cells was significantly decreased (P<0.001, N=5) when 
cells were treated with 1 nM paclitaxel in combination 
with either 10 μM EMD87580 (Fig. 4A), or 10 nM HMA 
(Fig 4B). This effect was significant when compared to 
cells treated with paclitaxel, EMD87580, or HMA alone 
at the same concentrations. Similar results were observed 
in MDA-MB-468 cells (P<0.001, N=5), but not in MCF7 
cells. In contrast, in unstimulated 231-WT cells, viability 
was not further reduced by the combination of paclitaxel 
and NHE inhibitors (not shown). Likewise, in 231-KO 
cells, no significant differences were observed between 
treatments; however, treatment with 1 nM paclitaxel alone 
slightly but significantly reduced viability (P<0.05, N=5). 
NHE1 inhibition enhances the effect of paclitaxel 
on cell migration of triple-negative breast cancer 
cells
We next examined the effect of NHE1 inhibition, 
in combination with paclitaxel, on cell migration in the 
three breast cancer cell lines. Stimulated (0.2% serum) 
231-WT cells, migrated at a rate approximately 20% 
faster than unstimulated (10% serum) cells at 18 hr. post-
Figure 2: Characterization of NHE1-knockout (231-
KO) MDA-MB-231 cells. A, B, Cell proliferation and 
viability in response to increasing paclitaxel doses was assessed 
by spectrophotometric analysis of MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) absorbance at 570 nm, 
with background subtraction at 630 nm. All data are presented 
as a ratio of mean OD values at indicated time points for each 
cell type relative to 0 hr. A, Proliferation of 231-WT and 231-
KO cells. In stimulated (0.2% serum) conditions, proliferation 
of knockout cells is not significantly different from parental 
MDA-MB-231 cells. However, both 231-WT and 231-KO cells 
are more proliferative over 48 hr. compared to MDA-MB-468 
(468) and MCF7 cells. B, Effect of paclitaxel on cell viability 
of 231-WT and 231-KO cells. Paclitaxel was significantly 
more cytotoxic to NHE1-knockout cells compared to parental 
MDA-MB-231 cells at concentrations of 0.1 nM and higher 
in stimulated conditions over 24 hours [*P<0.001, +P<0.01, 
#P<0.05, N=3]. In contrast, stimulated MDA-MB-468 and 
MCF7 cells did not show any changes in viability dependent on 
paclitaxel concentration.
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scratch (P<0.001, N=10, Fig. 5A, B), whereas stimulated 
MDA-MB-468 cells migrated at about 10% faster than 
unstimulated cells (P<0.01, N=10). No differences were 
observed in MCF7 migration between stimulated and 
unstimulated cells. Interestingly, unstimulated 231-
KO cells migrated faster than stimulated cells (P<0.05, 
N=10), a reversal of what is observed with the 231-WT. 
There was no difference in the rate of migration between 
unstimulated parental and NHE1-knockout MDA-MB-231 
cells. Notably, when stimulated 231-WT or MDA-MB-468 
cells were treated with paclitaxel in combination with 
either NHE1 inhibitor EMD87580 or HMA, a marked 
decrease in migration was observed (P<0.001, N=10, Fig. 
5C, D). However, no such effect of drug treatments was 
seen in stimulated 231-KO or MCF7 cells, or in any cell 
type in unstimulated conditions (not shown).
NHE1 promotes cell invasiveness and its 
inhibition potentiates effects of paclitaxel on cell 
invasiveness
Cell invasion assays were performed to gain insights 
into the role of NHE1 in invasion and metastasis of the 
various types of breast cancer cells. Cell invasion was 
significantly reduced in 231-KO cells compared to 231-
WT parental cells cultured in either stimulated (0.2% 
serum) or unstimulated (10% serum) conditions for 24 
hr. prior to invasion. Additionally, stimulation of cells by 
reduction of serum caused invasion to more than double in 
231-WT cells, but had no effect on 231-KO cells (P<0.001, 
N=4, Fig. 6A, B). A similar marked increase in invasive 
potential was seen in another triple-negative breast cancer 
cell line, MDA-MB-468 cells, with stimulation by reduced 
serum. No detectable invasion was observed in MCF7 
cells in this assay. 
We also determined the effect of NHE1 inhibition 
in combination with paclitaxel. When stimulated 231-
WT, 231-KO or MDA-MB-468 cells were treated with 
paclitaxel in the presence or absence of NHE1 inhibitors, 
EMD87580 or HMA, we found a significant reduction in 
the number of invading 231-WT and MDA-MB-468 cells 
after 24 hours (P<0.001, N=4, Fig. 6C, 6D), but no effect 
on 231-KO cells. 
Finally, we examined the role of NHE1 in a 
study of 3-dimensional long-term invasion by breast 
cancer cells. Cells were seeded onto a Matrigel matrix-
coated scaffold that enabled 3-dimensional growth and 
Figure 3: Effect of knocking out NHE1 on MDA-MB-231 xenograft tumor growth in female athymic nude mice. A, 
Average tumor volume over time in mice subcutaneously injected with either 231-WT or 231-KO cells. Suspensions of 231-WT and 231-
KO cells in Matrigel were subcutaneously injected into the right and left dorsal flanks of female athymic nude mice to determine their 
tumor-promoting potential. Tumor growth was monitored weekly and mice were euthanized at Day 60. Tumor volume was calculated 
based on the volume of a sphere (V = (4/3)πr3), or the length and width of the tumor mass (V = 0.5x X 2y, where x is the length and y is the 
width of the tumor mass). There were 4 mice per group: 7 of 8, and 3 of 8, tumor xenografts developed in the wild type and knockout group 
respectively. B, Excised tumors from all mice. 231-WT xenografted cells developed into significantly larger, heterogeneous tumors than the 
231-KO cells starting at Day 28 [#P<0.05, N=8], and showed a marked increase tumor growth after Day 35 [*P<0.01, N=8]. No significant 
tumor growth was observed in the knockout group. 
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proliferation, mimicking cell growth and association with 
the extracellular matrix in vivo. NHE1 knock out cells 
(231-KO) cells did not survive in serum-deprived (0.2% 
serum) conditions for 7 days in this assay, so the analysis 
was limited to serum-supplemented conditions. Here, 231-
WT cells grown in 10% serum showed significantly more 
invasion through and, greater proliferation within, the 
scaffold than 231-KO cells (Fig. 7). 
DISCUSSION
Both established and novel chemotherapeutic 
strategies can have limited success in the treatment of 
metastatic cancer, especially due to the development of 
multidrug resistance [23]. This is particularly apparent 
in the treatment of triple-negative breast cancer, which is 
negative for the expression of estrogen and progesterone 
receptors and HER2, and therefore not susceptible to 
hormone or HER2-targeted therapy. Experimentation 
has shown that enhanced NHE1 activity acidifies the 
extracellular pH, and promotes metastasis of highly 
invasive types of breast cancer cells [24-27]. The 
phenomenon of NHE1 activation and acidification 
promoting tumorigenesis and invasiveness is not specific 
to breast cancer and also occurs in various forms in 
malignant melanoma [28], in fibrosarcoma cells [29], 
and in human colon cancer cells [29]. It stands to reason, 
therefore, that manipulating the tumor microenvironment 
through the modulation of NHE1 activity could augment 
chemotherapy strategies and potentially lessen the 
incidence of multidrug resistance. This approach might 
prove useful wherever multidrug resistance occurs, in both 
triple negative and non-triple negative breast cancers. 
In the present study, we therefore investigated the 
role of NHE1 in breast cancer cell invasion, migration 
and in tumor formation. Additionally, we studied the role 
of NHE1 in susceptibility to paclitaxel, one of the most 
effective chemotherapy drugs used in the treatment of 
this disease. These studies represent the first work that 
utilizes a complete, stable, and functional knockout of 
NHE1 in metastatic MDA-MB-231 breast cancer cells. 
Unlike transient silencing of NHE1 with targeted siRNA 
or partial knockdown of NHE1 with targeted shRNA, we 
constructed a complete functional knockout of NHE1 
in MDA-MB-231 breast cancer cells using zinc finger 
nucleases, thus enabling both in vivo and in vitro analysis 
of the physiological role of the Na+/H+ exchanger. 
We characterized the role of NHE1 in culture 
conditions either supplemented with serum or serum 
deprived. Serum deprivation occurs in vivo in the tumor 
microenvironment and tumor cells respond differently 
than normal cells to low-serum culture conditions. For 
example, NHE1 becomes constitutively active when 
serum is depleted [30, 31]. We found that the relative 
Na+/H+ exchange activity in stimulated 231-WT cells 
was markedly higher compared to unstimulated cells, 
where a basal NHE1 activity was observed. We further 
demonstrated that this elevated NHE1 activity in 
stimulated cells was not due to an increased expression 
of the NHE1 protein. Instead, it must have been due 
to changes in the regulation of NHE1 consistent with 
Figure 4: Effect of paclitaxel in combination with 
NHE1 inhibitors on cell viability of wild type (231-WT) 
and NHE1-knockout (231-KO) MDA-MB-231 cells, 
and MDA-MB-468 (468) and MCF7 cells. Cells were 
treated for 24 hours in reduced (0.2%) serum media (stimulated 
conditions), with 1 nM paclitaxel (TAX), 10 μM EMD87580 
(EMD) (A), or 10 nM HMA (HMA) (B), or with both paclitaxel 
and EMD87580 (ET, A), or paclitaxel and HMA (HT, B) 
[*P<0.001, +P<0.01, N=5]. Media only control cells (CTRL) 
were left untreated. Viability was assessed by the catalytic 
conversion of yellow MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) to purple formazan in live cells. 
Spectrophotometric quantitation of this colorimetric change 
was recorded as the optical density of the sample at 570 nm, 
with background subtraction at 630 nm. All data are presented 
as a ratio of sample means over mean control values for each 
treatment for each cell type. In 231-KO cells, a significant loss of 
viability is observed when cells are treated with paclitaxel alone 
[+P<0.01, N=5]. In stimulated conditions, both triple-negative 
MDA-MB-231 and MDA-MB-468 cells showed significantly 
reduced viability when treated with paclitaxel in the presence of 
NHE1 inhibitors EMD87580 or HMA [*P<0.001, N=5]. MCF7 
cell viability, however, was unaffected by drug treatments.
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earlier observations [32]. Serum deprivation reduces 
lactate production in both non-tumorigenic (MCF10A) 
and tumorigenic (MCF7) breast epithelial cell lines, but 
while it inhibits NHE1 activity in the non-tumorigenic 
cells, depletion of serum stimulates exchanger activity 
in tumor cells. This was earlier reported to be dependent 
on phosphoinositide-3-kinase (PI3K), though it was not 
known if PI3K phosphorylates NHE1 directly or through 
some unknown intermediary [30]. Later observations 
indicated that serum deprivation activates NHE1 in breast 
cancer cells via a sequential RhoA/p160ROCK/p38MAPK 
signaling pathway, gated by direct protein kinase A 
phosphorylation and concurrent inhibition of RhoA [33]. 
Elevated activity of NHE1 in tumor cells can affect 
Figure 5: Effect of paclitaxel in combination with NHE1 inhibitors on cell migration of wild type (WT) and NHE1-
knockout (KO) MDA-MB-231, MDA-MB-468 (468) and MCF7 cells. The rate of closure of an induced gap was evaluated 
using a qualitative wound-healing assay as described in the Materials and Methods. A, Rate of gap closure in stimulated (STIM) (0.2% 
serum) and unstimulated (UNSTIM) (10% serum) 231-KO cells relative to 231-WT cells, and in comparison to MDA-MB-468 and MCF7 
cells. Stimulated 231-WT and MDA-MB-468 cells migrate faster than unstimulated cells [*P<0.001, #P<0.05, N=10]. In contrast, in 
231-KO cells, faster migration is observed in unstimulated conditions [*P<0.001, N=10]. B, Pictorial representation of gap closure (at 
10X magnification) in serum-deprived 231-WT and 231-KO cells over time. C, Combined effect of paclitaxel and NHE1 inhibitors on 
the rate of migration. 1 nM paclitaxel (TAX) was evaluated in combination with either HMA (10 nM) or EMD87580 (10 µM). Arbitrary 
measurements of gap closure (normalized to the untreated controls) were pooled over multiple independent experiments and quantified with 
Image Pro Plus software [*P<0.001, +P<0.01, #P<0.05, N=10]. D, Pictorial representation of gap closure (at 10X magnification) in serum-
deprived 231-WT cells treated with paclitaxel, either alone or in combination with EMD87580 or HMA at 18 hr.
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Figure 7: Long-term invasion is dependent on the expression of NHE1 in MDA-MB-231 breast cancer cells. A, 
Representative image of 231-WT and 231-KO cells in 3-dimensional scaffold over 7 days in 10% serum; arrow shows the direction of 
invasion from top to bottom of the scaffold. B, Summary of results showing the number of invading cells [*P<0.001, N=3]. 
Figure 6: Invasiveness of stimulated (0.2% serum) or unstimulated (10% serum) 231-WT, 231-KO, MDA-MB-468 or 
MCF7 cells treated with paclitaxel +/- NHE1 inhibitors. The rate of cell invasion was determined using a Matrigel-coated Boyden 
chamber porous insert as described in the Materials and Methods. A, Invasiveness of 231-KO cells, +/- stimulation, relative to 231-WT 
cells, and in comparison to MDA-MB-468 (468) and MCF7 cells [*P<0.001, N=4]. Side panel (B) illustrates representative images. C, 
Effect of paclitaxel (1 nM, TAX) in combination with NHE1 inhibitors (10 µM EMD87580 or 10 nM HMA) on cell invasion in wild type 
and NHE1-knockout MDA-MB-231, and MDA-MB-468 cells [*P<0.001, N=4]. D, Illustration of invasion of stimulated 231-WT cells. 
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intracellular ion concentrations. In vivo, the activity of Na+ 
transporters would result in cellular alkalinization that is 
typical of tumor cells [34]. This results in a concomitant 
increase in sodium loading. In cardiomyocytes [35], and 
malignant gliomas [36], this increased NHE1 activity and 
elevated intracellular Na+ causes elevated intracellular Ca2+ 
through reversed activity of the Na+/Ca+2 exchanger [37]. 
How important this pathway is in tumor cells is unclear at 
this time, however, it is known that two important protein 
regulators of NHE1, calmodulin and CHP (calcineurin 
regulatory protein) are calcium dependent in their 
association. One isoform of CHP, CHP2 is upregulated in 
tumor cells and the CHP2-NHE1 interaction is suggested 
to be key in maintenance of the cellular alkalinization 
associated with malignantly transformed cells [38]. 
Further studies are ongoing to characterize the complex 
regulation of NHE1 in breast cancer cells.
When we examined the role of NHE1 in triple-
negative breast cancer cells overall, our results showed 
that NHE1 has a facilitative role in breast cancer invasion 
and metastasis, as well as a chemo-protective role in 
highly invasive triple-negative breast cancer cells. These 
metastasis-enhancing roles were not apparent in less 
invasive, non-triple-negative, breast cancer cells. The 
evidence for this statement comes from experiments both 
in vivo and in vitro, and from experiments in which we 
knocked out the NHE1 protein or inhibited its activity. 
In summary, the experiments suggesting that NHE1 
facilitates metastatic breast cancer are: 1, knockout of 
NHE1 reduced the in vivo tumor-promoting capability of 
MDA-MB-231 cells; 2, NHE1 deletion in MDA-MB-231 
cells reduced their invasive capacity; and 3, specific 
inhibition of NHE1 potentiated the effect of paclitaxel, 
reducing cell viability, invasion and migration. These are 
discussed below.
1, NHE1-Knockout: Knocking out NHE1 from the 
highly tumorigenic MDA-MB-231 cells significantly 
reduces their tumor-promoting capability in vivo. This 
was demonstrated by the differences in subcutaneous 
growth of tumor xenografts of parental and knockout cells 
in athymic nude mice. Interestingly, despite comparable 
rates of proliferation between the parental and NHE1-
knockout cells in vitro, little or no tumor development was 
apparent in xenografts of 231-KO cells. These results are 
the first such demonstration of the critical role of NHE1 in 
tumor development of triple-negative breast cancer cells 
in vivo. In this study, we also demonstrated that in an in 
vitro invasion assay, NHE1-knockout cells were unable to 
survive serum-depleted conditions over seven days. This 
might account for their inability to promote tumor growth 
in vivo. 
2, Loss of NHE1 reduces cell migration and 
invasion of triple-negative breast cancer cells: Knockout 
of NHE1 from MDA-MB-231 cells dramatically 
decreased the migratory capacity of these cells, an effect 
that is independent of their rates of proliferation over 18 
hours. In addition, the invasive potential of these normally 
aggressively invasive breast cancer cells was markedly 
reduced with the deletion of NHE1. Even in the presence 
of serum, NHE1-knockout cells were significantly less 
invasive through an extracellular matrix than parental 
cells, particularly over several days, as shown by the 
3-dimensional invasion assay data. This confirms that 
NHE1 is critical to the molecular mechanisms involved in 
invasion. Notably, while the viability of stimulated 231-
WT cells was unaffected by increasing doses of paclitaxel, 
deletion of NHE1 in the knockout cells (231-KO) made 
them more susceptible to paclitaxel-mediated cell death (at 
doses upwards of 0.1 nM), suggesting a chemo-protective 
role for NHE1 in MDA-MB-231 cells.
3, Specific inhibition of NHE1 potentiates effects 
of paclitaxel: We found that two structurally different 
NHE1 inhibitors, EMD87580 [(2-methyl-4,5-di-
(methylsulfonyl)-benzoyl)-guanidine], and HMA [5-(N, 
N-hexamethylene)-amiloride] specifically potentiated 
effects of paclitaxel on triple-negative breast cancer cells. 
This included effects on cell migration, viability and 
invasion when the combinatorial treatment of paclitaxel 
in the presence of NHE1 inhibitors was applied to MDA-
MB-231 cells. Here, we found that paclitaxel alone 
caused a slight but significant decrease in the migration 
of stimulated triple-negative MDA-MB-231 and MDA-
MB-468 breast cancer cells. However, when paclitaxel 
was used in the presence of NHE1 inhibitors, its effect 
was greatly enhanced. Likewise, paclitaxel, EMD87580, 
and HMA alone, all had an effect on the invasiveness of 
these cells when stimulated, however, when paclitaxel was 
used in combination with an NHE1 inhibitor, the reduction 
in the rate of invasion was much more pronounced. These 
effects did not occur in non-triple-negative MCF7 breast 
cancer cells.
Our results are a novel finding with human 
breast cancer cells. While one study has shown that the 
amiloride analogue DMA, (5-(N,N-dimethyl) amiloride-
hydrochloride) potentiates paclitaxel-mediated apoptosis 
[39], it is now known that MDA-MB-435 are in fact a 
melanoma cell line [40]. Nevertheless, those results 
support the idea that NHE1 inhibition can enhance the 
effects of paclitaxel on cancer cells. The concept of 
inhibiting NHE1 activity as a potential strategy to augment 
existing chemotherapeutic treatment of tumor cells, and 
in the management of tumor size, is intriguing. Our 
experimental design used NHE1 inhibition with paclitaxel 
treatment at doses much lower than the established IC
50
 
of 2.4 nM for paclitaxel in MDA-MB-231 cells [41]. 
The beneficial effects did not occur in unstimulated cells, 
where the rate of NHE1 exchanger activity is minimal. 
It therefore appears that this combinatorial treatment 
effect may be contingent upon NHE1 hyper-activation, 
as occurs when cells are serum-deprived in the tumor 
microenvironment. Remarkably, these effects were also 
observed in the moderately invasive, triple-negative, 
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basal-like MDA-MB-468 breast cancer cells, albeit to 
a lesser extent. In contrast, we did not observe a similar 
trend with the lowly invasive, hormone receptor-positive, 
luminal MCF7 cells, at least with the drug concentrations 
used in the present study. These data suggest that the 
observed effects may be specific to triple-negative breast 
cancers which have a constitutively activated NHE1 
protein in the disease state [32]. 
The potential of NHE1 as a target in the development 
of novel anti-cancer therapeutics was recently reviewed, 
highlighting key characteristics of NHE1 that could 
be exploited to combat the tumorigenic and metastatic 
capacity of cancer cells [42]. The NHE1 gene, SLC9A1 
is a redox regulated gene. Down-regulation of NHE1 
expression decreases the capacity of cells to recover 
from an acute acid load and sensitizes them to cell death 
triggers [43]. One approach to down-regulation of NHE1 
may be through PPAR (peroxisome proliferator-activated 
receptor). A peroxisome proliferator response element was 
identified in the promoter region of the NHE1. Expression 
of PPARγ (peroxisome proliferator-activated receptor γ) 
is increased in breast cancer cell lines and primary breast 
tumors, and correlates with an acidic intracellular pH and 
it was suggested that judicious use of PPARγ ligands at 
low doses could have significant anti-cancer effects in 
combination with chemotherapy [44]. Whether or not 
the anti-cancer effects of down-regulation of NHE1 gene 
expression are comparable to the chemical inhibition of 
NHE1 activity, has yet to be explored in depth. 
In this study, we suggest that NHE1 inhbition 
may reduce the acidic extracellular pH of the tumor 
microenvironment, thereby rendering paclitaxel more 
effective. Could inhibition of NHE1 in vivo also 
improve the efficacy of paclitaxel treatment? This idea 
is supported by evidence suggesting that another NHE1 
inhibitor, amiloride-HCl, though it has low NHE1 
specificity, still might have anti-cancer properties [14]. 
Certainly, NHE1 inhibitors have been used in clinical 
trials involving heart disease, however, there are still 
challenges left before their use is approved [45]. Possibly, 
the development of more selective NHE1 inhibitors, or 
inhibitors that specifically target tumor cells, might be 
productive in the treatment of breast cancer. The more 
potent of new highly selective NHE1 inhibitors includes: 
cariporide, (N-(Diaminomethylene)-4-isopropyl-3-
(methylsulfonyl)benzamide); the phenoxazine derivative 
Phx-3 (2-aminophenoxazine-3-one); and Compound 9t 
(5-aryl-4-(4-(5-methyl-1H-imidazol-4-yl)piperididn-1-
yl)pyrimidine analog). The efficacies and specificity for 
NHE1 inhibition of these compounds and their potential 
for use in future clinical and/or pre-clinical trials should 
be considered for the treatment of triple-negative breast 
cancer, as well as for BRCA1-positive breast cancer. 
Indeed, the use of selective NHE1 inhibitors can be 
applied to the treatment of other human malignant tumors 
in attempts to not only prevent tumor formation, but also 
circumvent multidrug resistance [16, 27]. 
Since pH regulation plays an integral role in 
the tumor microenvironment, it is highly plausible to 
consider the modulation of Na+/H+ exchanger activity 
as a means of increasing the efficacy of chemotherapy, 
particularly for triple-negative breast cancer, for which 
targeted therapies do not currently exist. Realistically, 
this synergistic approach using NHE1 inhibitors as co-
adjuvants to established chemotherapeutic drugs, could 
arguably be effective in augmenting the targeted treatment 
of the HER2-positive subtype of breast cancer as well. 
Future experiments could address this in multiple breast 
cancer subtypes. Moreover, modulating the pH of the 
tumor microenvironment could conceivably decrease the 
incidence and spread of multidrug resistance for anti-
cancer agents in general. Overall, our data highlight a 
novel putative, clinical role for NHE1 inhibitors targeted 
to modulate pH in the tumor microenvironment and to 
maximize the efficacy of breast cancer chemotherapy.
MATERIALS AND METHODS
Cell lines and culture conditions
Parental MDA-MB-231 (231-WT), 231-KO (NHE1-
knockout), MDA-MB-468 and MCF7 cells were cultured 
in high-glucose modified DMEM (HyClone) supplemented 
with 10% fetal calf serum (HyClone), 10 mM HEPES, 
and 1000 units/ml penicillin/streptomycin (Gibco) under 
standard culture conditions (5% CO
2
, 37°C and high 
humidity). Starvation media was supplemented with 0.2% 
serum but otherwise identical in composition. Paclitaxel 
(Taxol®, Sigma) and NHE1 inhibitors, EMD87580 
[2-methyl-4,5-di-(methylsulfonyl)-benzoylguanidine, 
gift from Merck] and HMA [5-(N, N-hexamethylene)-
amiloride, Sigma], were used at indicated concentrations. 
MDA-MB-231, MDA-MB-468 and MCF7 cell lines were 
authenticated by DNA analysis (DDC Medical, Ohio) and 
showed >95% homology to the ATCC STR profile.
Generation of 231-KO (NHE1-knockout) cells
In MDA-MB-231 cells, endogenous NHE1 
was excised using CompoZr® Knockout Zinc Finger 
Nucleases (Sigma-Aldrich) specifically designed to target 
the human NHE1 gene SLC9A1, and according to the 
manufacturers’ protocols. Potential knockout cells were 
screened by western blot using anti-NHE1 antibody (BD 
Transduction Laboratories) and re-selected using the 
proton suicide assay as described earlier [46]. Briefly, cells 
are incubated in a Na+-free lithium chloride (LiCl) buffer 
for two hours to allow for NHE1-mediated uptake of Li+ 
in the absence of Na+, which results in acidification of the 
extracellular pH. LiCl buffer is then replaced with choline 
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chloride buffer for one hour. NHE1 is unable to transport 
choline, resulting in the reversal of proton exchange across 
the plasma membrane and acidification of intracellular pH. 
Intracellular proton accumulation becomes lethal in cells 
with a functional exchanger whereas NHE1-knockout 
cells survive, thereby ensuring the purity of the 231-KO 
cell line.
Xenograft tumor growth experiments
All animal experiments/husbandry were approved 
and follow the guidelines of the Canadian Animal Care 
and Use Committee. Subcutaneous injection of tumor 
cells was carried out as previously described [47]. 
Parental MDA-MB-231 and NHE1-knockout (231-
KO) cells were grown to confluence in 100 mm2 culture 
dishes, washed in phosphate-buffered saline (PBS), 
trypsinized, and resuspended in complete media. After 
centrifugation at 1000 rpm for 5 min, cells were washed 
once in PBS and resuspended in a 4:1 mixture of serum-
free media:Matrigel (BD #354234, 10 mg/ml of LDEV-
free matrix). Two hundred microliter (containing ~ 2.5 X 
106 cells) of cells:Matrigel suspension was subcutaneously 
injected into the right and left dorsal flanks of female 
athymic nude mice (Taconic Laboratories; #NCRNU-F, 
CrTac:NCr-FoxN1Nu) to determine the tumor-promoting 
potential of the 231-WT and 231-KO breast cancer cells. 
Mice were monitored weekly to assess tumor growth and 
euthanized at Day 60. Tumor volume was calculated based 
on the volume of a sphere (V = [4/3)πr3] or the length 
and width of the tumor mass (V = 0.5x X 2y, where x is 
the length and y is the width of the tumor mass) wherever 
appropriate. 
Western blotting
Total protein from whole cell lysates was separated 
by 10% SDS polyacrylamide gels and transferred onto 
nitrocellulose membranes. Blots were incubated overnight 
with anti-NHE1 antibody (BD Transduction Laboratories) 
and anti-actin antibody (Santa Cruz Biotechnologies) was 
used as a loading control. Image J software was used to 
quantify NHE1 expression.
Na+/H+ exchange activity (pHi) assay: 
Intracellular pH measurement
The pH-sensitive dye BCECF-AM 
(2’,7’-bis(carboxyethyl)-5(6)-carboxyfluorescerin-
acetoxymethyl ester) was used to measure intracellular 
pH (pHi) as described earlier [48]. Briefly, cells were 
grown to 80% confluence on rectangular glass coverslips 
(22 × 11 mm) in 35 mm dishes in complete media. Once 
attached, cells were either serum-starved (stimulated) 
or not (unstimulated) for 24 hr. prior to loading with 
BCECF-AM for 20 minutes at 37°C. BCECF-AM is a 
cell permeable, non-fluorescent dye that is de-esterified 
to BCECF upon entry into cells. In cellulo, BCECF 
fluoresces in response to changes in intracellular pH. After 
incubation with BCECF, followed by incubation in a Na+-
containing equilibration buffer for 3 min, an acute acid 
load is induced by treating cells with ammonium chloride 
(50 mM × 3 min). After removal of NH4Cl, followed by 
reperfusion with Na+-free and Na+-containing buffers, 
cells are placed in Na+-free calibration buffer containing 
nigericin and high K+ to calibrate signal ratios at pH 6, 
7 and 8. The rate of recovery of pHi as indicated by the 
ratio of BCECF fluorescence post-excitation at 440 nm 
and 502 nm, and emission at 528 nm, was recorded using 
a PTI Deltascan Illumination System (Photon Technology 
International, New Jersey, USA). NHE1 activity was 
calculated from the slope of the first 20 sec of recovery 
from acidification and was expressed as ∆pH/sec. 
Background drift in the absence of Na+ was subtracted 
from rates of recovery in the presence of Na+, and all 
data were normalized to controls to show relative Na+/H+ 
exchange activity between cell types. Buffering capacity 
was calculated and shown to be similar across all cell 
types. 
Cytotoxicity, Viability and Proliferation assays
Cells were seeded in 96-well plates at a density of 1 
x 105 cells/well, and left untreated (control) or treated with 
paclitaxel and/or NHE1 inhibitors EMD87580 or HMA in 
phenol red-free high-glucose modified DMEM (HyClone) 
media supplemented with either 10% (unstimulated cells) 
or 0.2% (stimulated cells) fetal calf serum and incubated 
for 0 to 48 hr. under standard culture conditions. Unless 
otherwise noted, drug concentrations were used as follows: 
paclitaxel (1 nM), EMD (10 μM) and HMA (10 nM). MTT 
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide, Sigma] assays with a final MTT concentration 
of 0.5 mg/ml were used to assess cytotoxicity to drugs, 
resultant cell viability (at 24 hr.) and proliferation (at 0, 24, 
48 hr.). Absorbance was measured with a BioTek Synergy 
MX microplate reader (BioTek Instruments Inc.) at 570 
nm and background (at a reference wavelength of 630 
nm) was subtracted. All viability data were normalized to 
untreated controls. Proliferation data was represented as 
a measure of the increase in the rate of cell proliferation 
from time 0 hr.
Migration assay
Cell migration was studied using the qualitative 
wound-healing assay. Briefly, cells were seeded in 
24-well plates (0.5 x 106 cells/well), and grown to 
confluence, before wounding was induced with a pipette 
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tip. Cells were washed with PBS to remove unattached 
cells, supplemented with media, and either left untreated 
(control), or treated with paclitaxel and/or NHE1 inhibitors 
with either 10% (unstimulated cells) or 0.2% (stimulated 
cells) serum and incubated for 0 to 24 hr. Images were 
acquired at 0, 18 and 24 hr. time-points. Arbitrary 
measurements of gap closure were quantified with Image 
Pro Plus software using a Leica DM IRB microscope (at 
10X magnification). A minimum of three images/well and 
five measurements/image was acquired for each treatment; 
all treatments were done in triplicate. Data shown are 
a representation of decrease in gap distance at 18 hr. 
compared to the initial measurement at 0 hr over multiple 
independent experiments.
Invasion assays
Cell invasion assays were performed using 
Boyden chamber 8 μm porous inserts (Corning) coated 
with Matrigel (BD Biosciences) according to the 
manufacturer’s recommendations. Briefly, cells were 
either serum-starved (stimulated) or not (unstimulated) 
and/or treated with appropriate drugs for 24 hr. prior to 
adding 1 × 105 cells per insert. Reservoir media contained 
10% serum to promote chemotaxis. After 24 hr., cells 
on the upper surface of the insert were removed with a 
cotton swab and invading cells on the lower surface 
were fixed in 3.7% paraformaldehyde, permeabilized in 
100% methanol, and stained with Giemsa. Invasion was a 
measure of how many cells traversed the membrane, and 
was imaged at 10X magnification with Image Pro Plus 
software using a Leica DM IRB microscope. Data shown 
are a representation of 3 to 5 fields/insert over multiple 
independent experiments. 3D invasion assays were carried 
out with 6-well Alvetex® scaffold inserts (Reinnervate, 
UK), which were coated with Matrigel according to 
manufacturer’s instructions. Briefly, inserts were pre-
treated with 70% ethanol to prime scaffolds for cell 
culture. After washing in PBS, scaffolds were coated with 
0.8 mg/ml of Matrigel prior to adding cells. Cells were 
seeded at a density of 1 x 106 cells in 100 μL of media 
per insert and allowed to attach to the scaffold surface for 
90 minutes prior to adding media. Serum supplemented 
media (10%) was added for the first 24 hr. to facilitate 
initial cell adhesion. After 24 hr., media was changed and 
cells were either serum-starved (stimulated, 0.2% serum) 
or not (unstimulated, 10% serum). Cells were allowed 
to invade through the scaffold over 7 days with media 
changes every 2 days. Scaffold discs were then excised 
from the insert, embedded in paraffin, and longitudinally 
sectioned into multiple 10 μm sections prior to staining 
with hematoxylin and eosin. Invasion was a measure of 
how many cells traversed the scaffold, and was imaged 
at 20X magnification with a Zeiss ApoTome Microscope 
and Zeiss AxioCam MRm imaging software. Data shown 
are a representation of triplicate sections per slide with 
two slides per treatment of each scaffold disc, and three 
independent experiments.
Statistical Analysis
All data are expressed as means ± SEM and plotted 
with KaleidaGraph 4.1 (Synergy Software, PA, US). Data 
shown are a mean of N=3 to 10 independent experiments. 
Statistical analysis was carried out using the two-way 
analysis of variance (ANOVA) to compare data between 
groups with GraphPad Prism 5.0 (GraphPad Software, CA, 
US). Post hoc comparisons were made using Bonferroni’s 
multiple-comparison tests. A P value less than 0.05 was 
considered to be significant. 
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isoform 1; PIP
2
: Phosphatidylinositol biphosphate; TAX: 
Paclitaxel (Taxol®).
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